AB
MLYS icon

Amalgamated Bank’s Mineralys Therapeutics MLYS Stock Holding History

Amalgamated Bank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,470
Closed -$53K – 2349
2025
Q4 		$53K Buy
1,470
+485
+49% +$19.4K ﹤0.01% 1824
2025
Q3 		$37K Hold
985
– – ﹤0.01% 1931
2025
Q2 		$13K Hold
985
– – ﹤0.01% 2319
2025
Q1 		$16K Buy
985
+303
+44% +$3.48K ﹤0.01% 2158
2024
Q4 		$8K Hold
682
– – ﹤0.01% 2554
2024
Q3 		$8K Hold
682
– – ﹤0.01% 2563
2024
Q2 		$8K Buy
682
+181
+36% +$2.28K ﹤0.01% 2563
2024
Q1 		$6K Sell
501
-1,241
-71% -$15.3K ﹤0.01% 2658
2023
Q4 		$15K Sell
1,742
-149
-8% -$1.17K ﹤0.01% 2769
2023
Q3 		$18K Buy
1,891
+450
+31% +$5.87K ﹤0.01% 2707
2023
Q2 		$25K Sell
1,441
-102
-7% -$1.52K ﹤0.01% 2628
2023
Q1 		$24K Buy
+1,543
New +$26K ﹤0.01% 2579

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Amalgamated Bank's MLYS Position: Q1 2026 in Review

Amalgamated Bank sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 1,470 shares — an estimated $53K sold.

Amalgamated Bank first reported a position in MLYS in Q1 2023 and held it in 12 quarters. The position peaked at $53K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Amalgamated Bank reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,470 Mineralys Therapeutics shares in Q1 2026, an estimated $53K.
  • Amalgamated Bank first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 12 quarters.
  • Amalgamated Bank's Mineralys Therapeutics position peaked at $53K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.